Alteogen has developed its own biosimilar technology, including cell lines, production processes, and analytical methods, to create a pipeline of biosimilars with equivalent efficacy to original protein drugs but at lower costs.
Alteogen’s NexP sustained-release technology uses human alpha-1 antitrypsin (A1AT), a protein abundant in human blood, as a carrier to extend the half-life of biopharmaceuticals.
Alteogen’s Hybrozyme technology enhances the flexibility and stability of protein structures while preserving the original enzyme’s functional mechanisms.
Jeon Tae-yeon holds a PhD in biochemistry from the University of Wisconsin and conducted molecular endocrinology research during his postdoctoral studies. He later served as a research professor at Indiana University School of Medicine, focusing on cardiovascular disease research. After graduating from law school, he became a registered patent attorney in the United States.
Alteogen, founded in 2008, researches and develops next-generation biobetters with improved efficacy over existing biologics and biosimilars with equivalent efficacy.
Alteogen focuses on research and development of next-generation biobetters with improved features over existing biologics and biosimilars using its proprietary platform technologies.
